Trials / Completed
CompletedNCT01107964
Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Milton S. Hershey Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize that oral omega-3-acid ethyl esters (Lovaza, GlaxoSmithKline, Research Triangle Park, NC) will decrease dry-eye related symptoms as well as clinical markers associated with dry eye disease (Schirmer-1 test values, positive vital staining with lissamine green, and fluorescein tear break-up time) when compared to administration of placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oral Omega-3-acid ethyl esters | 1 gram capsule by mouth four times daily for 45 days |
| DRUG | Placebo corn oil capsule | 1 gram by mouth 4 times daily for 45 days |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2014-08-01
- Completion
- 2015-06-15
- First posted
- 2010-04-21
- Last updated
- 2017-12-22
- Results posted
- 2017-12-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01107964. Inclusion in this directory is not an endorsement.